Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Primary relevance to vitamin D Vitamin D is a stated subject of this paper.

Vitamin D is a stated subject of this paper; the supporting source evidence is shown below.

Why this paper is included

Supporting source evidence:

This study aims to evaluate the efficiency of calcium and vitamin D in treating adults diagnosed with osteoporosis caused by corticosteroid therapy.

Source: Abstract. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Review / evidence synthesis.

Review / evidence synthesis

Reviews existing research; the exact review methods need further assessment.

Meta-analysis unclear · Blinding not applicable to this review · Research setting awaiting verification

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

Publisher article type: review-article

Source: Publisher publication metadata.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Full studies

Evaluation of the efficiency of calcium and vitamin D in treating adults with corticosteroid-induced osteoporosis

Review / evidence synthesis · Medicine · 2021

Original publication title

Evaluation of the efficiency of calcium and vitamin D in treating adults with corticosteroid-induced osteoporosis

Song-Li Pan; Chen-Cui Li; Hong-Wang Cui; Wen-Xian Wang; Chun-Hong Li

Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

The results of this study will provide further evidence about calcium and vitamin D in treating adults with corticosteroid-induced osteoporosis, clinicians and policymakers can make practical use of the results.

An extract from the source publication. Read it in context.

At a glance

Study background

What background does the paper provide?

Osteoporosis is a condition that deteriorates the skeletal system progressively and systemically. The indicators include diminished bone mass and micro-architectural deterioration of bone tissue. Resultantly, the bones are increasingly fragile and highly prone to fractures.[1] The incidence of fractures related to osteoporosis increases sharply with age, from 4% in females aged 50 to 59 to 52% in females aged more than 80 years.[2] Numerous risk factors are related to the development of osteoporosis, such as gender, age, genetic factors, ethnicity, reproductive status, reduced intake of calcium, unhealthy lifestyle, and certain illnesses.[3] Individuals having inflammatory disorders face an elevated risk of developing osteoporosis due to their underlying diseases and frequent intake of corticosteroids.

Steroids are widely utilized as a treatment method for bronchial asthma, inflammatory bowel disease, rheumatic disorders, organ transplants, malignant lymphomas, and multiple myeloma. Corticosteroid therapy suppresses the formation of bones and impedes the absorption of Calcium in the intestine, which leads to bone loss and fractures and ultimately to secondary hyperparathyroidism and elevated osteoclastic bone resorption.[4,5] Histomorphometrically, the bone formation rate and trabecular bone volume are reduced.[6] The objectives of treatment include averting bone fractures, sustaining the BMD, and refining physical functions.

Calcium and vitamin D are regarded to be at the core of the treatment process in post-menopausal osteoporosis.[3] Several studies investigated how Calcium and Vitamin D affected adult patients with corticosteroid-induced osteoporosis; however, the reported results are not conclusive.[7Not reported10] Thus, this study will be undertaken to evaluate the efficiency of calcium and vitamin D in treating adult patients with corticosteroid-induced osteoporosis.

Source: Introduction

Study methods

What methods does the paper describe?

2.1

Study registration

This study is funded through a protocol registry in the Open Science Framework (OSF, http://osf.io/). The registration DOI number is 10.17605/OSF.IO/ZVB38. The protocol follows the Preferred Reporting Items for Systematic Reviews and Meta-Analysis Protocol statement guidelines.

2.2

Inclusion criteria for study selection

2.2.1
Types of studies

Regardless of the publication status, this review will include all available studies based on the study method of randomized controlled trials (RCTs) that evaluates the efficacy of calcium and vitamin D in treating adults with corticosteroid-induced osteoporosis. The language was restricted to publications in English. Case reports, conferences, reviews, non-RCTs, and non-human studies will be excluded.

2.2.2
Types of participants

All study subjects identified with osteoporosis are included. Patients must take corticosteroids throughout the trial. Patients who had received calcitonin, anti-coagulant drug therapy, and those with any illnesses that might affect bone metabolism will be excluded.

2.2.3
Types of interventions

All study participants will be administered vitamin D with calcium as opposed to vitamin D only, calcium only, or placebo in treating adult patients with corticosteroid-induced osteoporosis.

2.2.4
Types of outcome measures

In this review, the principal outcome measure includes a percentage variation in bone mineral density from the reference. The secondary outcome measures include drop-outs due to side effects, fracture incidence, and 24 hours hydroxyproline excretion.

2.3

Data sources and search strategy

2.3.1
Electronic searches

Studies that evaluate the efficiency of calcium and vitamin D in treating adults with corticosteroid-induced osteoporosis will be sourced from PubMed, EMBASE, the Cochrane Library, Scopus, and Web of Science. The time scope is limited from their inception to November 2020. The combination of keywords and free text retrieval is adopted. The following key terms will be used for the search: osteoporosis∗, corticosteroid∗, steroids∗, calcium∗, “vitamin D”.

2.3.2
Other resources

Moreover, this study will also refer to the reference lists of the selected studies and search ClinicalTrials.gov (www.ClinicalTrials.gov) and Google scholar to find grey literature.

2.4

Data collection and analysis

2.4.1
Selection of studies

Based on the eligibility criteria defined previously, 2 authors will autonomously screen the related studies. Once any duplicates are removed, the titles and abstracts and will be examined. Following a review of the full-text of the preliminary selective papers, the selection of eligible studies is based on our pre-determined inclusion criteria. All disagreements will be resolved through discussion. Figure 1. illustrates the details of the entire selection process.

Figure 1

The research flowchart.

Figure image at the original source: open the original paper. This file is not included in this text import.
2.4.2
Data extraction and management

Data extraction will be performed autonomously by 2 authors. The process will use a standard designed data extraction table. The following information will be extracted: first author, publication date, race, gender, disease duration, study method, sample size, intervention details, outcomes, and other associated information. All disagreements will be resolved through discussion.

2.4.3
Risk of bias assessment

The risk of bias in the included studies will be autonomously evaluated by 2 authors, the process will be based on the Cochrane Collaboration's “Risk of bias” tool.[11]

2.4.4
Measures of treatment effect

Risk ratios with 95% confidence interval will be used to calculate dichotomous outcomes, and mean difference or standardized mean difference (SMD) with 95% confidence interval to calculate continuous outcomes.

2.4.5
Assessment of heterogeneity

I2 statistic and the Cochrane's Q test will be used to estimate the heterogeneity among the included studies. Accordingly, an I2 > 50% or P < .1 infers substantial heterogeneity, in which case, the random-effects model will be adopted to merge the results; else, the fixed-effects model is adopted to merge the results.

2.4.6
Assessment of reporting biases

If the number of include studies is more than ten, funnel plots are used to assess the risk of publication bias.[12]

2.4.7
Sensitivity analysis

It is planned to carry out a sensitivity analysis to evaluate the robustness of our findings by excluding low-quality studies.

Source: Methods Source: Methods Source: Methods Source: Methods

Abstract: Ethics and dissemination

Since this systematic review does not involve any human or animal participants, an ethics approval is not required.

Source: Ethics and dissemination:

Abstract: Systematic review registration

Discussion

To date, there are no reports for evaluating the efficiency of calcium and vitamin D in treating adults with corticosteroid-induced osteoporosis. Recently, an increasing number of studies have investigated the efficacy of calcium and vitamin D for treating adults with corticosteroid-induced osteoporosis. However, the results of these studies are not conclusive. Therefore, this study is conducted to investigate the efficiency of Calcium and Vitamin D in treating adult patients with corticosteroid-induced osteoporosis. Furthermore, this study also provides helpful recommendations for clinicians and future research on using calcium and vitamin D to treat adult patients with corticosteroid-induced osteoporosis.

Source: Discussion

Abstract: Results

This study will provide additional practical and targeted results of evaluating the efficiency of calcium and vitamin D in treating adults with corticosteroid-induced osteoporosis.

Source: Results:

Abstract: Conclusion

The results of this study will provide further evidence about calcium and vitamin D in treating adults with corticosteroid-induced osteoporosis, clinicians and policymakers can make practical use of the results.

Source: Conclusion:
Authors’ abstract

Abstract

Background:

Administering corticosteroid is an effective therapeutic strategy for treating most inflammatory conditions. However, there is a chance for corticosteroid treatment to adversely affect bones, resulting in corticosteroid-induced osteoporosis, which is a highly prevalent type of secondary osteoporosis. Elevated bone resorption and reduced formation of bone are pathogenesis indicators of corticosteroid-induced osteoporosis. Preventative therapy is recommended for patients initiating steroids. This study aims to evaluate the efficiency of calcium and vitamin D in treating adults diagnosed with osteoporosis caused by corticosteroid therapy.

Methods:

Electronic databases will be searched systematically to source studies that have evaluated the efficiency of calcium and vitamin D as a treatment method for adult patients with osteoporosis from corticosteroid therapy. The databases include, PubMed, EMBASE, the Cochrane Library, Scopus, and Web of Science. The timeline of the search will be limited from inception to November 2020. This study will utilize the Cochrane risk of bias tool to assess the quality of the studies reviewed. Moreover, appropriate methods will be chosen to analyze the data.

The RevMan 5.3 software is utilized to perform statistical analysis.

Results:

This study will provide additional practical and targeted results of evaluating the efficiency of calcium and vitamin D in treating adults with corticosteroid-induced osteoporosis.

Conclusion:

The results of this study will provide further evidence about calcium and vitamin D in treating adults with corticosteroid-induced osteoporosis, clinicians and policymakers can make practical use of the results.

Ethics and dissemination:

Since this systematic review does not involve any human or animal participants, an ethics approval is not required.

Systematic review registration:

Aug 19, 2021. osf.io/zvb38. (https://osf.io/zvb38/).

Read the full paper
1

Introduction

Osteoporosis is a condition that deteriorates the skeletal system progressively and systemically. The indicators include diminished bone mass and micro-architectural deterioration of bone tissue. Resultantly, the bones are increasingly fragile and highly prone to fractures.[1] The incidence of fractures related to osteoporosis increases sharply with age, from 4% in females aged 50 to 59 to 52% in females aged more than 80 years.[2] Numerous risk factors are related to the development of osteoporosis, such as gender, age, genetic factors, ethnicity, reproductive status, reduced intake of calcium, unhealthy lifestyle, and certain illnesses.[3] Individuals having inflammatory disorders face an elevated risk of developing osteoporosis due to their underlying diseases and frequent intake of corticosteroids.

Steroids are widely utilized as a treatment method for bronchial asthma, inflammatory bowel disease, rheumatic disorders, organ transplants, malignant lymphomas, and multiple myeloma. Corticosteroid therapy suppresses the formation of bones and impedes the absorption of Calcium in the intestine, which leads to bone loss and fractures and ultimately to secondary hyperparathyroidism and elevated osteoclastic bone resorption.[4,5] Histomorphometrically, the bone formation rate and trabecular bone volume are reduced.[6] The objectives of treatment include averting bone fractures, sustaining the BMD, and refining physical functions.

Calcium and vitamin D are regarded to be at the core of the treatment process in post-menopausal osteoporosis.[3] Several studies investigated how Calcium and Vitamin D affected adult patients with corticosteroid-induced osteoporosis; however, the reported results are not conclusive.[7Not reported10] Thus, this study will be undertaken to evaluate the efficiency of calcium and vitamin D in treating adult patients with corticosteroid-induced osteoporosis.

2

Methods

2.1

Study registration

This study is funded through a protocol registry in the Open Science Framework (OSF, http://osf.io/). The registration DOI number is 10.17605/OSF.IO/ZVB38. The protocol follows the Preferred Reporting Items for Systematic Reviews and Meta-Analysis Protocol statement guidelines.

2.2

Inclusion criteria for study selection

2.2.1
Types of studies

Regardless of the publication status, this review will include all available studies based on the study method of randomized controlled trials (RCTs) that evaluates the efficacy of calcium and vitamin D in treating adults with corticosteroid-induced osteoporosis. The language was restricted to publications in English. Case reports, conferences, reviews, non-RCTs, and non-human studies will be excluded.

2.2.2
Types of participants

All study subjects identified with osteoporosis are included. Patients must take corticosteroids throughout the trial. Patients who had received calcitonin, anti-coagulant drug therapy, and those with any illnesses that might affect bone metabolism will be excluded.

2.2.3
Types of interventions

All study participants will be administered vitamin D with calcium as opposed to vitamin D only, calcium only, or placebo in treating adult patients with corticosteroid-induced osteoporosis.

2.2.4
Types of outcome measures

In this review, the principal outcome measure includes a percentage variation in bone mineral density from the reference. The secondary outcome measures include drop-outs due to side effects, fracture incidence, and 24 hours hydroxyproline excretion.

2.3

Data sources and search strategy

2.3.1
Electronic searches

Studies that evaluate the efficiency of calcium and vitamin D in treating adults with corticosteroid-induced osteoporosis will be sourced from PubMed, EMBASE, the Cochrane Library, Scopus, and Web of Science. The time scope is limited from their inception to November 2020. The combination of keywords and free text retrieval is adopted. The following key terms will be used for the search: osteoporosis∗, corticosteroid∗, steroids∗, calcium∗, “vitamin D”.

2.3.2
Other resources

Moreover, this study will also refer to the reference lists of the selected studies and search ClinicalTrials.gov (www.ClinicalTrials.gov) and Google scholar to find grey literature.

2.4

Data collection and analysis

2.4.1
Selection of studies

Based on the eligibility criteria defined previously, 2 authors will autonomously screen the related studies. Once any duplicates are removed, the titles and abstracts and will be examined. Following a review of the full-text of the preliminary selective papers, the selection of eligible studies is based on our pre-determined inclusion criteria. All disagreements will be resolved through discussion. Figure 1. illustrates the details of the entire selection process.

Figure 1

The research flowchart.

Figure image at the original source: open the original paper. This file is not included in this text import.
2.4.2
Data extraction and management

Data extraction will be performed autonomously by 2 authors. The process will use a standard designed data extraction table. The following information will be extracted: first author, publication date, race, gender, disease duration, study method, sample size, intervention details, outcomes, and other associated information. All disagreements will be resolved through discussion.

2.4.3
Risk of bias assessment

The risk of bias in the included studies will be autonomously evaluated by 2 authors, the process will be based on the Cochrane Collaboration's “Risk of bias” tool.[11]

2.4.4
Measures of treatment effect

Risk ratios with 95% confidence interval will be used to calculate dichotomous outcomes, and mean difference or standardized mean difference (SMD) with 95% confidence interval to calculate continuous outcomes.

2.4.5
Assessment of heterogeneity

I2 statistic and the Cochrane's Q test will be used to estimate the heterogeneity among the included studies. Accordingly, an I2 > 50% or P < .1 infers substantial heterogeneity, in which case, the random-effects model will be adopted to merge the results; else, the fixed-effects model is adopted to merge the results.

2.4.6
Assessment of reporting biases

If the number of include studies is more than ten, funnel plots are used to assess the risk of publication bias.[12]

2.4.7
Sensitivity analysis

It is planned to carry out a sensitivity analysis to evaluate the robustness of our findings by excluding low-quality studies.

3

Discussion

To date, there are no reports for evaluating the efficiency of calcium and vitamin D in treating adults with corticosteroid-induced osteoporosis. Recently, an increasing number of studies have investigated the efficacy of calcium and vitamin D for treating adults with corticosteroid-induced osteoporosis. However, the results of these studies are not conclusive. Therefore, this study is conducted to investigate the efficiency of Calcium and Vitamin D in treating adult patients with corticosteroid-induced osteoporosis. Furthermore, this study also provides helpful recommendations for clinicians and future research on using calcium and vitamin D to treat adult patients with corticosteroid-induced osteoporosis.

Author contributions

Conceptualization: Song-Li Pan.

Data curation: Song-Li Pan, Chen-Cui Li, Hong-Wang Cui, Wen-Xian Wang, Chun-Hong Li.

Formal analysis: Song-Li Pan, Chen-Cui Li, Hong-Wang Cui, Wen-Xian Wang, Chun-Hong Li.

Funding acquisition: Song-Li Pan, Chun-Hong Li.

Investigation: Chen-Cui Li, Wen-Xian Wang, Chun-Hong Li.

Methodology: Song-Li Pan, Chen-Cui Li, Hong-Wang Cui, Chun-Hong Li.

Project administration: Song-Li Pan, Wen-Xian Wang, Chun-Hong Li.

Resources: Hong-Wang Cui, Chun-Hong Li.

Software: Song-Li Pan, Chen-Cui Li, Hong-Wang Cui, Wen-Xian Wang.

Supervision: Wen-Xian Wang, Chun-Hong Li.

Validation: Song-Li Pan, Chen-Cui Li, Hong-Wang Cui.

Visualization: Song-Li Pan, Chun-Hong Li.

Writing: original draft: Song-Li Pan, Chun-Hong Li.

Writing: review & editing: Chun-Hong Li.

How to cite this article: Pan SL, Li CC, Cui HW, Wang WX, Li CH. Evaluation of the efficiency of calcium and vitamin D in treating adults with corticosteroid-induced osteoporosis: a protocol for systematic review and meta-analysis. Medicine. 2021;100:39(e27197).

S-LP and C-CL contributed equally to this work.

This work was supported by a grant from the Natural Science Foundation of Hainan Province (Grant Number: 817140). The sponsors had no role in the present protocol.

The authors have no conflicts of interests to disclose.

The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

References

[1] Baccaro LF Conde DM Costa-Paiva L Pinto-Neto AM . The epidemiology and management of postmenopausal osteoporosis: a viewpoint from Brazil . Clin Interv Aging 2015 ;10 :583Not reported91 . 25848234 10.2147/CIA.S54614 PMC4374649
[2] Tella SH Gallagher JC . Prevention and treatment of postmenopausal osteoporosis . J Steroid Biochem Mol Biol 2014 ;142 :155Not reported70 . 24176761 10.1016/j.jsbmb.2013.09.008 PMC4187361
[3] Eriksen EF Halse J Moen MH . New developments in the treatment of osteoporosis . Acta Obstet Gynecol Scand 2013 ;92 :620Not reported36 . 22646526 10.1111/j.1600-0412.2012.01473.x
[4] Chotiyarnwong P McCloskey EV . Pathogenesis of glucocorticoid-induced osteoporosis and options for treatment . Nat Rev Endocrinol 2020 ;16 :437Not reported47 . 32286516 10.1038/s41574-020-0341-0
[5] Adler RA . Glucocorticoid-induced osteoporosis: management challenges in older patients . J Clin Densitom 2019 ;22 :20Not reported4 . 29941355 10.1016/j.jocd.2018.03.004
[6] Compston J . Glucocorticoid-induced osteoporosis: an update . Endocrine 2018 ;61 :07Not reported16 . 10.1007/s12020-018-1588-2 PMC5997116 29691807
[7] Adachi JD Bensen WG Bianchi F . Vitamin D and calcium in the prevention of corticosteroid induced osteoporosis: a 3 year followup . J Rheumatol 1996 ;23 :995Not reported1000 . 8782129
[8] Buckley LM Leib ES Cartularo KS Vacek PM Cooper SM . Calcium and vitamin D3 supplementation prevents bone loss in the spine secondary to low-dose corticosteroids in patients with rheumatoid arthritis. A randomized, double-blind, placebo-controlled trial . Ann Intern Med 1996 ;125 :961Not reported8 . 8967706 10.7326/0003-4819-125-12-199612150-00004
[9] Sambrook P Birmingham J Kelly P . Prevention of corticosteroid osteoporosis. A comparison of calcium, calcitriol, and calcitonin . N Engl J Med 1993 ;328 :1747Not reported52 . 7684512 10.1056/NEJM199306173282404
[10] Sambrook PN Kotowicz M Nash P . Prevention and treatment of glucocorticoid-induced osteoporosis: a comparison of calcitriol, vitamin D plus calcium, and alendronate plus calcium . J Bone Miner Res 2003 ;18 :919Not reported24 . 12733733 10.1359/jbmr.2003.18.5.919
[11] Higgins JP Altman DG Gøtzsche PC . The Cochrane Collaboration's tool for assessing risk of bias in randomised trials . BMJ 2011 ;343 :d5928 . 22008217 10.1136/bmj.d5928 PMC3196245
[12] Begg CB Mazumdar M . Operating characteristics of a rank correlation test for publication bias . Biometrics 1994 ;50 :1088Not reported101 . 7786990
Publication and source details

Original title: Evaluation of the efficiency of calcium and vitamin D in treating adults with corticosteroid-induced osteoporosis

Song-Li Pan; Chen-Cui Li; Hong-Wang Cui; Wen-Xian Wang; Chun-Hong Li

Medicine · 2021

∗ Correspondence: Chun-Hong Li, The First Affiliated Hospital of Hainan Medical University, 31, Longhua RD, Haikou 570102, Hainan, China (e-mail: lichunhong19831201@163.com).Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.2021https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0Natural Science Foundation of Hainan Province817140Song-Li Pan

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T11:58:05.882691+00:00

DOI: 10.1097/md.0000000000027197 · PMC8483843